Presidio Pharmaceuticals, Inc. Successfully Completes Phase 1 Proof-of-Concept for PPI-668, its Potent HCV NS5A Inhibitor, in Hepatitis C Patients With Genotype-1 Infection

SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. announced today successful completion of Phase 1b clinical testing of its lead HCV NS5A inhibitor in patients with HCV genotype-1 infection, with positive efficacy and safety observations supporting advancement of PPI-668 to Phase 2 combination studies.